AEON
AEON Biopharma, Inc.·Healthcare
0.84
1.205%(+0.01)
Market ClosedLast Updated: — ET
52W L: $0.3852W H: $1.45
AEON NEWS
globenewswire.com
Apr 3
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that, on April 2, 2026, in connection with the appointment of John Bencich as Chief Financial Officer, the Company's Compensation Committee of the Board of Directors (the “Compensation Committee”) approved the grant of inducement awards.
globenewswire.com
Apr 3
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that on March 31, 2026, it received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that, following its year-end financial results, the Company is not in compliance with an additional continued listing standard set forth in the NYSE American Company Guide (the “Company Guide”).
globenewswire.com
Mar 30
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Prog
defenseworld.net
Mar 25
AEON Biopharma (AEON) Projected to Post Quarterly Earnings on Wednesday
AEON Biopharma (NASDAQ: AEON - Get Free Report) is anticipated to release its results before the market opens on Wednesday, April 1st. Analysts expect AEON Biopharma to post earnings of ($0.17) per share for the quarter. AEON Biopharma Price Performance AEON opened at $1.06 on Wednesday. AEON Biopharma has a 12 month low of $0.38 and
defenseworld.net
Feb 27
Financial Analysis: MindWalk (NASDAQ:HYFT) versus AEON Biopharma (NASDAQ:AEON)
AEON Biopharma (NASDAQ: AEON - Get Free Report) and MindWalk (NASDAQ: HYFT - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation. Institutional and Insider Ownership 22.8% of AEON Biopharma
globenewswire.com
Jan 21
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
- AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today voted in favor of the proposals required to complete the transactions announced in November, including the consummation of the PIPE financing and the related Daewoong note exchange - IRVINE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA), today reported on two separate positive events for the Company: AEON confirmed that earlier today it held its scheduled BPD Type 2a meeting with FDA, in line with prior guidance.
